Alx Oncology Holdings (ALXO) EBT (2019 - 2026)
Alx Oncology Holdings (ALXO) posted EBT of -$21.6 million for Q1 2026, up 5.3% sequentially from -$22.8 million in Q4 2025, and up 29.68% YoY from -$16.7 million in Q1 2025.
Alx Oncology Holdings (ALXO) EBT (2019 - 2026) Analysis & Trends
Alx Oncology Holdings has reported EBT for 8 years, with the latest figure at -$21.6 million in Q1 2026.
- Quarterly EBT rose 29.68% year-over-year to -$21.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$95.7 million (up 27.86% YoY) and the FY2025 annual result came in at -$497000.0, up 99.63% from the prior year.
- EBT rose to -$21.6 million in Q1 2026 per ALXO's latest filing, from -$22.8 million in the prior quarter.
- Over five years, EBT peaked at -$21.6 million in Q1 2026 and troughed at -$51.0 million in Q3 2023.
- A 5-year average of -$32.9 million and a median of -$30.7 million in 2025 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2024: EBT plunged 1555.03% in 2022, then surged 39.77% in 2024.
- Over 5 years, EBT stood at -$30.6 million in 2022, then slumped by 49.01% to -$45.7 million in 2023, then jumped by 36.11% to -$29.2 million in 2024, then increased by 21.74% to -$22.8 million in 2025, then rose by 5.3% to -$21.6 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$21.6 million, -$22.8 million, and -$22.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Alx Oncology Holdings | 270.90 Mn | 270.90 Mn | - | -17.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.67 Mn |
| Mar 31, 2026 | -21.62 Mn |
| Dec 31, 2025 | -22.83 Mn |
| Sep 30, 2025 | -22.14 Mn |
| Jun 30, 2025 | -29.13 Mn |
| Mar 31, 2025 | -30.74 Mn |
| Dec 31, 2024 | -29.17 Mn |
| Sep 30, 2024 | -30.71 Mn |
| Jun 30, 2024 | -42.06 Mn |
| Mar 31, 2024 | -38.42 Mn |
| Dec 31, 2023 | -45.66 Mn |
| Sep 30, 2023 | -50.99 Mn |
| Jun 30, 2023 | -37.37 Mn |
| Mar 31, 2023 | -31.83 Mn |
| Dec 31, 2022 | -30.64 Mn |
| Sep 30, 2022 | -35.31 Mn |
| Jun 30, 2022 | -34.44 Mn |
| Mar 31, 2022 | -25.52 Mn |
| Dec 31, 2021 | 2.11 Mn |
| Sep 30, 2021 | -24.57 Mn |